Caseware UK (AP4) 2023.0.135 2023.0.135 trueThe members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.false0No description of principal activity2023-03-010truefalse SC469359 2023-03-01 2024-02-29 SC469359 2022-03-01 2023-02-28 SC469359 2024-02-29 SC469359 2023-02-28 SC469359 c:Director2 2023-03-01 2024-02-29 SC469359 d:CurrentFinancialInstruments 2024-02-29 SC469359 d:CurrentFinancialInstruments 2023-02-28 SC469359 d:CurrentFinancialInstruments d:WithinOneYear 2024-02-29 SC469359 d:CurrentFinancialInstruments d:WithinOneYear 2023-02-28 SC469359 d:RetainedEarningsAccumulatedLosses 2024-02-29 SC469359 d:RetainedEarningsAccumulatedLosses 2023-02-28 SC469359 d:RetainedEarningsAccumulatedLosses 2022-03-01 SC469359 c:FRS102 2023-03-01 2024-02-29 SC469359 c:AuditExempt-NoAccountantsReport 2023-03-01 2024-02-29 SC469359 c:FullAccounts 2023-03-01 2024-02-29 SC469359 c:CompanyLimitedByGuarantee 2023-03-01 2024-02-29 SC469359 e:Euro 2023-03-01 2024-02-29 iso4217:GBP xbrli:pure

Registered number: SC469359










International Society of Oncology and Biomarkers
(A company limited by guarantee)








Unaudited

Financial statements

Information for filing with the registrar

For the Year Ended 29 February 2024

 
International Society of Oncology and Biomarkers
 
(A company limited by guarantee)
Registered number: SC469359

Balance sheet
As at 29 February 2024

29 February
28  February 
2024
2023
Note

  

Current assets
  

Cash at bank and in hand
 4 
570,697
608,808

  
570,697
608,808

Creditors: amounts falling due within one year
 5 
(4,600)
(4,350)

Net current assets
  
 
 
566,097
 
 
604,458

Total assets less current liabilities
  
566,097
604,458

  

  

Net assets excluding pension asset
  
566,097
604,458

Net assets
  
566,097
604,458


Capital and reserves
  

Profit and loss account brought forward
  
604,458
670,994

Loss for the year
  
(38,361)
(66,536)

Profit and loss account carried forward
  
566,097
604,458

  
566,097
604,458


The director considers that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The director acknowledges his responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the income statement in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf on 30 July 2024.




R J Moro
Director

The notes on pages 2 to 4 form part of these financial statements.

Page 1

 
International Society of Oncology and Biomarkers

(A company limited by guarantee)
 

 
Notes to the financial statements
For the Year Ended 29 February 2024

1.


General information

The company is limited by guarantee and incorporated and domiciled in Scotland. Its registered office is Westby, 64 West High Street, Forfar, DD8 1BJ and its principal place of business is in the UK.

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with FRS 102 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland' and the requirements of the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The preparation of financial statements in compliance with FRS 102 requires the use of certain critical accounting estimates. It also requires management to exercise judgment in applying the Company's accounting policies.

The following principal accounting policies have been applied:

 
2.2

Going concern

The financial statements have been prepared on the going concern basis following the Director's review of the organisations future activites and the strong financial position of the organisation.  

 
2.3

Incoming resources

Income comprises revenue recognised by the company in respect of membership subscriptions, royalty income, congress attendance and investment income.
All membership subscriptions and congress income is recognised in the year to which it relates. Amounts received by the balance sheet date in respect of future years are deferred and income earned during the year but not received by the balance sheet date is accrued.
Royalty income, which is generally earned based upon a percentage of sales or a fixed amount per product sold, is recognised on an accrual basis.

 
2.4

Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

 
2.5

Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.

Page 2

 
International Society of Oncology and Biomarkers

(A company limited by guarantee)
 

 
Notes to the financial statements
For the Year Ended 29 February 2024

2.Accounting policies (continued)

 
2.6

Foreign currency translation

Functional and presentation currency

The Company's functional and presentational currency is € Euro.

Transactions and balances

Foreign currency transactions are translated into the functional currency using the spot exchange rates at the dates of the transactions.

At each period end foreign currency monetary items are translated using the closing rate. Non-monetary items measured at historical cost are translated using the exchange rate at the date of the transaction and non-monetary items measured at fair value are measured using the exchange rate when fair value was determined.


3.


Employees




The Company has no employees other than the directors, who did not receive any remuneration (2023 - €NIL).

The average monthly number of employees, including directors, during the year was 0 (2023 - 0).


4.


Cash and cash equivalents

29 February
28 February
2024
2023

Cash at bank and in hand
570,697
608,808



5.


Creditors: Amounts falling due within one year

29 February
28 February
2024
2023

Accruals and deferred income
4,600
4,350


Page 3

 
International Society of Oncology and Biomarkers

(A company limited by guarantee)
 

 
Notes to the financial statements
For the Year Ended 29 February 2024


6.


Company status

The company is a private company limited by guarantee and consequently does not have share capital. 
In the event of the dissolution of the organisation, all remaining assets of the organisation will be used exclusively for the scientific purpose of furthering knowledge in oncology, by funding the work and/or interactions of scientists in this field of endeavor. The board will suggest a proposal for the disbursement  of funds and all monetary and non monetary resources, which will be voted upon by the General Assembly.


7.


Controlling party

The company is controlled by its members.


Page 4